Tubo-on, Michael N.
HRN: 27-41-75 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/04/2025
CO-AMOXICLAV 625MG (TAB)
07/04/2025
07/10/2025
PO
625mg
BID
Lacerated Wound, Frontal Area
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes